Drug intelligence / Profile preview

EG-001

Development stage: Preclinical
Lead developer: Lantheus

Overview

EG-001 is a preclinical-stage drug candidate being developed by Enhanced Genomics for the treatment of Alzheimer's disease. The therapeutic asset is being discovered and developed using Enhanced Genomics' proprietary 3D multi-omics platform, which maps long-range chromatin interactions and promoter-enhancer contacts to identify and validate novel disease-driving targets in specific brain cell types, such as microglia. Development of the program is supported by a strategic partnership with the Alborada Drug Discovery Institute at the University of Cambridge.

Beyond the preview

Go deeper on EG-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EG-001.

Explore the full profile